Plasma low-molecular-weight proteome profiling identified neuropeptide-y as a prostate cancer biomarker polypeptide

Journal of Proteome Research

Volumn 12, Issue 10, 2013, Pages 4497-4506

  Ueda, Koji ^a   Tatsuguchi, Ayako ^a   Saichi, Naomi ^a   Toyama, Atsuhiko ^b   Tamura, Kenji ^c   Furihata, Mutsuo ^d   Takata, Ryo ^e   Akamatsu, Shusuke ^f   Igarashi, Masahiro ^g   Nakayama, Masato ^h   Sato, Taka Aki ^b   Ogawa, Osamu ^f   Fujioka, Tomoaki ^e   Shuin, Taro ^c   Nakamura, Yusuke ⁱ   Nakagawa, Hidewaki ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b SHIMADZU CORPORATION   (Japan)

^c KOCHI MEDICAL SCHOOL HOSPITAL   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h TOPPAN PRINTING CO LTD   (Japan)

ⁱ SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

Biomarker; label free quantification; low molecular weight; mass spectrometry; plasma; prostate cancer; PSA

Indexed keywords

NEUROPEPTIDE Y;

ALKYLATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOREACTIVITY; LIMIT OF DETECTION; MENTAL STRESS; MOLECULAR WEIGHT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

AGED; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NEOPLASM GRADING; NEUROPEPTIDE Y; PROSTATIC NEOPLASMS; PROTEOME; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84885195796     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400547s     Document Type: Article

References (32)

1. Ablin, R. J.; Pfeiffer, L.; Gonder, M. J.; Soanes, W. A. Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate Exp. Med. Surg. 1969, 27 (4) 406-10
2. Catalona, W. J.; Smith, D. S.; Ratliff, T. L.; Dodds, K. M.; Coplen, D. E.; Yuan, J. J.; Petros, J. A.; Andriole, G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N. Engl. J. Med. 1991, 324 (17) 1156-61
3. Chou, R.; Croswell, J. M.; Dana, T.; Bougatsos, C.; Blazina, I.; Fu, R.; Gleitsmann, K.; Koenig, H. C.; Lam, C.; Maltz, A.; Rugge, J. B.; Lin, K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann. Intern. Med. 2011, 155 (11) 762-71
4. Brett, A. S.; Ablin, R. J. Prostate-cancer screening - what the U.S. Preventive Services Task Force left out N. Engl. J. Med. 2011, 365 (21) 1949-51
5. Kurogochi, M.; Matsushista, T.; Amano, M.; Furukawa, J.; Shinohara, Y.; Aoshima, M.; Nishimura, S. Sialic acid-focused quantitative mouse serum glycoproteomics by multiple reaction monitoring assay Mol. Cell. Proteomics 2010, 9 (11) 2354-68
6. Ueda, K.; Takami, S.; Saichi, N.; Daigo, Y.; Ishikawa, N.; Kohno, N.; Katsumata, M.; Yamane, A.; Ota, M.; Sato, T. A.; Nakamura, Y.; Nakagawa, H. Development of serum glycoproteomic profiling technique; simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes Mol. Cell. Proteomics 2010, 9 (9) 1819-28
7. Villanueva, J.; Martorella, A. J.; Lawlor, K.; Philip, J.; Fleisher, M.; Robbins, R. J.; Tempst, P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age Mol. Cell. Proteomics 2006, 5 (10) 1840-52
8. Ueda, K.; Saichi, N.; Takami, S.; Kang, D.; Toyama, A.; Daigo, Y.; Ishikawa, N.; Kohno, N.; Tamura, K.; Shuin, T.; Nakayama, M.; Sato, T. A.; Nakamura, Y.; Nakagawa, H. A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma PloS One 2011, 6 (4) e18567
9. Shen, Y.; Liu, T.; Tolic, N.; Petritis, B. O.; Zhao, R.; Moore, R. J.; Purvine, S. O.; Camp, D. G.; Smith, R. D. Strategy for degradomic-peptidomic analysis of human blood plasma J. Proteome Res. 2010, 9 (5) 2339-46
10. Liu, T.; Qian, W. J.; Mottaz, H. M.; Gritsenko, M. A.; Norbeck, A. D.; Moore, R. J.; Purvine, S. O.; Camp, D. G., 2nd; Smith, R. D. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry Mol. Cell. Proteomics 2006, 5 (11) 2167-74
11. Mouton-Barbosa, E.; Roux-Dalvai, F.; Bouyssie, D.; Berger, F.; Schmidt, E.; Righetti, P. G.; Guerrier, L.; Boschetti, E.; Burlet-Schiltz, O.; Monsarrat, B.; Gonzalez de Peredo, A. In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification Mol. Cell. Proteomics 2010, 9 (5) 1006-21
12. Capriotti, A. L.; Caruso, G.; Cavaliere, C.; Piovesana, S.; Samperi, R.; Lagana, A. Comparison of three different enrichment strategies for serum low molecular weight protein identification using shotgun proteomics approach Anal. Chim. Acta 2012, 740, 58-65
13. Hood, B. L.; Lucas, D. A.; Kim, G.; Chan, K. C.; Blonder, J.; Issaq, H. J.; Veenstra, T. D.; Conrads, T. P.; Pollet, I.; Karsan, A. Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model J. Am. Soc. Mass Spectrom. 2005, 16 (8) 1221-30
14. Lassout, O.; Pastor, C. M.; Fetaud-Lapierre, V.; Hochstrasser, D. F.; Frossard, J. L.; Lescuyer, P. Analysis of the pancreatic low molecular weight proteome in an animal model of acute pancreatitis J. Proteome Res. 2010, 9 (9) 4535-44
15. Wu, J.; An, Y.; Pu, H.; Shan, Y.; Ren, X.; An, M.; Wang, Q.; Wei, S.; Ji, J. Enrichment of serum low-molecular-weight proteins using C18 absorbent under urea/dithiothreitol denatured environment Anal. Biochem. 2010, 398 (1) 34-44
16. Wang, Y. Y.; Lee, C. T.; Lu, C. L.; Chen, C. Y.; Chang, F. Y.; Lee, S. D.; Doong, M. L.; Wang, P. S. Gastric inhibitory polypeptide appears less important in mediating acid secretion Hepato-Gastroenterology 1999, 46 (27) 2105-9
17. Sehested, A.; Juul, A. A.; Andersson, A. M.; Petersen, J. H.; Jensen, T. K.; Muller, J.; Skakkebaek, N. E. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels J. Clin. Endocrinol. Metab. 2000, 85 (4) 1634-40
18. Di Iorio, R.; Marinoni, E.; Letizia, C.; Villaccio, B.; Alberini, A.; Cosmi, E. V. Adrenomedullin production is increased in normal human pregnancy Eur. J. Endocrinol. 1999, 140 (3) 201-6
19. Su, A. I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K. A.; Block, D.; Zhang, J.; Soden, R.; Hayakawa, M.; Kreiman, G.; Cooke, M. P.; Walker, J. R.; Hogenesch, J. B. A gene atlas of the mouse and human protein-encoding transcriptomes Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (16) 6062-7
20. Pepe, M. S.; Cai, T.; Longton, G. Combining predictors for classification using the area under the receiver operating characteristic curve Biometrics 2006, 62 (1) 221-9
21. Choi, J. S.; Min, J. S. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients Yonsei Med. J. 1997, 38 (1) 1-7
22. Gerl, A.; Lamerz, R.; Clemm, C.; Mann, K.; Hartenstein, R.; Wilmanns, W. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin. Cancer Res. 1996, 2 (9) 1565-70
23. Meyer, T.; Rustin, G. J. Role of tumour markers in monitoring epithelial ovarian cancer Br. J. Cancer 2000, 82 (9) 1535-8
24. Zhang, L.; Bijker, M. S.; Herzog, H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer Pharmacol. Ther. 2011, 131 (1) 91-113
25. Hirsch, D.; Zukowska, Z. NPY and stress 30 years later: the peripheral view Cell. Mol. Neurobiol. 2012, 32 (5) 645-59
26. Sah, R.; Geracioti, T. D. Neuropeptide Y and posttraumatic stress disorder Mol. Psychiatry 2013, 18 (6) 646-55
27. Ruscica, M.; Dozio, E.; Motta, M.; Magni, P. Relevance of the neuropeptide Y system in the biology of cancer progression Curr. Top. Med. Chem. 2007, 7 (17) 1682-91
28. Rasiah, K. K.; Kench, J. G.; Gardiner-Garden, M.; Biankin, A. V.; Golovsky, D.; Brenner, P. C.; Kooner, R.; O'Neill, G, F.; Turner, J. J.; Delprado, W.; Lee, C. S.; Brown, D. A.; Breit, S. N.; Grygiel, J. J.; Horvath, L. G.; Stricker, P. D.; Sutherland, R. L.; Henshall, S. M. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis Cancer Epidemiol., Biomarkers Prev. 2006, 15 (4) 711-6
29. Gittelman, M.; Hertzman, B.; Bailen, J.; Williams, T.; Koziol, I.; Henderson, R. J.; Efros, M.; Bidair, M.; Ward, J. F. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study J. Urol. 2013, 190 (1) 64-69
30. Ochiai, A.; Okihara, K.; Kamoi, K.; Oikawa, T.; Shimazui, T.; Murayama, S. I.; Tomita, K.; Umekawa, T.; Uemura, H.; Miki, T. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy BJU Int. 2013, 111 (6) 928-33
31. Qu, X.; Randhawa, G.; Friedman, C.; O'Hara-Larrivee, S.; Kroeger, K.; Dumpit, R.; True, L.; Vakar-Lopez, F.; Porter, C.; Vessella, R.; Nelson, P.; Fang, M. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer Cancer Genet. 2013, 206 (1-2) 1-11
32. Laxman, B.; Morris, D. S.; Yu, J.; Siddiqui, J.; Cao, J.; Mehra, R.; Lonigro, R. J.; Tsodikov, A.; Wei, J. T.; Tomlins, S. A.; Chinnaiyan, A. M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res. 2008, 68 (3) 645-9